language_icon
EN
HI

Alembic Share price

ALEMBICLTD

89.95

1.39 (-1.52%)
NSE
BSE
Last updated on 15 May, 2026 | 15:57 IST
Today's High

92.10

Today's Low

89.62

52 Week Low

0.00

52 Week High

92.10

Zero AMC

Free Demat with Zero AMC*

Open a Free Demat Account
+ Free 1st Year AMC

Alembic Chart

Alembic Share Key Metrics

Volume
1.09 L
Market Cap
2309.75 CR
LTQ@LTP
74@89.95
ATP
90.66
Var Margin
17.82 %
Circuit Range
73.08-109.6
Delivery %
- %
Value
99.00 L
ASM/GSM
No
Market Lot
1

Summary

Alembic share price is ₹89.95 as of 16 May, 2026. The stock Alembic intraday movement has stayed between ₹89.62 and ₹92.10, while on a 52-week basis,Alembic price 52 week high is ₹92.10 & its 52 week low is ₹0.00.
In terms of trading activity, Alembic has recorded a volume of 109204 shares, The Alembic has a market cap of ₹256781828 CR. The stock’s Average Traded Price (ATP) stands at ₹90.66, while the Last Traded Quantity at Last Traded Price (LTQ@LTP) is 74 @ ₹89.95.
Alembic operates within a circuit range of ₹73.08 – ₹109.60, with a Value of ₹99.00 L. The Delivery Percentage for the day is -1%. Additionally, Alembic currently falls under the No framework, and trades with a market lot size of 1.

Alembic Fundamentals

View More
P/E Ratio

7.24

P/B Ratio

0.9

Div. Yield

2.67

Sector P/E

62.93

Sector P/B

-16.12

Sec. Div. Yield

0.19

Alembic Resistance and Support

Pivot 90.93

Resistance

First Resistance

92.16

Second Resistance

92.98

Third Resistance

94.21

Support

First Support

90.11

Second Support

88.88

Third Support

88.06

Alembic Shareholding Pattern

View More
  • 2016-17
  • 2018-19
  • 2019-20
  • 2020-21
  • 2021-22
  • 2022-23
  • 2023-24
  • 2024-25
  • 2025-26
  • 2026-27
Total Promoters
Segment
Percent

Total Promoters

70.88%

Mutual Fund

0%

Insurance

0%

Foreign Institutional Investors

1.25%

Domestic Institutional Investors

0.04%

Retail

27.83%

Others

0%

Total Promoters
MAR '26
70.88%

Alembic Corporate Actions

DateAgenda
2026-05-19Audited Results & Final Dividend
2026-02-12Quarterly Results
2025-11-10Quarterly Results
2025-08-12Quarterly Results & Other
2025-05-13Audited Results & Final Dividend
2025-02-07Quarterly Results & Other

Alembic News

Alembic Pharma Q4 profit up 29% as US formulations business grows 11%; declares ₹12 dividend

Alembic Pharma reported a 29% year-on-year increase in its Q4 net profit, driven by an 11% growth in its US formulations business. The company also declared a final dividend of ₹12 per equity share for the financial year ended March 31, 2026.
May 15 2026 15:05:00

Alembic Pharma shares rise on USFDA nod for prostate cancer drug with $3 billion estimated market size

Alembic Pharmaceuticals has received USFDA tentative approval for its Darolutamide Tablets, 300 mg, a prostate cancer medication that is therapeutically equivalent to Bayer's Nubeqa. This approval targets an estimated US$3.155 billion market for the twelve-month period ending March 2026, contingent upon the expiry of patent protections or exclusivity periods.
May 14 2026 11:05:00

Alembic Ltd - 506235 - Board Meeting Intimation for Considering Audited Financial Results For The Quarter And Financial Year Ended 31St March, 2026

Alembic Limited's Board of Directors will hold a meeting on May 19, 2026. The agenda includes considering and approving the audited financial results for the quarter and financial year ended March 31, 2026, and recommending a dividend on Equity Shares.
May 08 2026 12:05:00

Alembic Pharma gets USFDA nod for Fingolimod capsules; targets $145 million market

Alembic Pharmaceuticals Limited has received final approval from the USFDA for its Fingolimod Capsules, 0.5 mg. This generic version of Novartis' Gilenya targets the relapsing forms of multiple sclerosis, representing an estimated US$145 million market opportunity for the 12 months ending December 2025. This approval is a significant milestone, bringing Alembic's total USFDA ANDA approvals to 237.
Apr 25 2026 12:04:00
Read More

About Alembic

NSE : 79  
BSE : 506235  
ISIN : INE426A01027  

The Company was established on 30th July 1907. Originallyit was manufacturing chemicals liquor etc. However from1950''s onwards it ventured into pharmaceutical businessin the production of bulk drugs. The Company may beconsidered as pioneer in manufacturing penicillin throughfermentation process by developing indigenous know-how. TheCompany was conferred Sir P. C. Ray award for indigenousmanufacturing of Penicillin. Over the years Company hasalso developed other bulk drugs like ErythromycinRoxithromycin and Azithromycin. The Company is also in theformulations market and is producing number of items intherapeutic segments of which some of the products are themarket leaders. The Company also gas large exports and hasalso won awards from CHEMEXIL for export performance in theyear 1991-92. It has also been recognised as Export Houseby Government of India. It is an exporter of Penicillinformulations to Germany and U.K. which are major producersof Penicillin. The Company started a Veterinary Divisionfor animal health care in 1986 and as per the ORG report(1994) they are ranked 6th in the domestic Veterinarymarket. The Company took over Neomer Limited in 1986-87which produces synthetic Fibre and yarn. Alembic Chemical''smain plant is located at Alembic Road Vadodara whichmanufactures bulk drugs and majority of the formulations.Other plant for pharmaceuticals is at Village PanelavDist. Panchmahals in Gujarat State and has modernequipment and machinery. The Company''s Neomer division hasits plant at Panelav. The company has developed schoolshospitals sports club consumer co-operative societyresidential colonies etc. The company is one of thelargest pharmaceutical companies in India and is ranked 6thin terms of pharmaceutical formulations as per (OperationsResearch Group) ORG Report of December 1995.PRESENT BUSINESS OF THE COMPANYThe Company is engaged in the manufacture of basic drugspharmaceuticals and antibiotic formulations (both for humanconsumption and animal health care). The major basic/bulkdrugs manufactured are Penicillin ErythromycinRoxithromycin and Azithromycin. The Company has thefollowing range of products:a. Bulk Drugs - These cover Penicillin ErythromycinAzithromycin Roxithromycin etc. used for formulationslike tablets capsules injectables etc.b. Antibiotic Formulations : These cover Penicillininjections and other combinations for tablets granulesointments pediatric drops etc.c. Pharmaceutical Formulations : These cover cough and coldremedies analgesics anti malarials anti-diarrhoealstonics Vitamin formulations etc.d. Other consumable products - These cover GlycodinSharkoferrol Nervitone Protinules etc.e. The Neomer Division of the Company manufactures mainlyPolypropylene Staple Fibre.

Read More

Alembic Management

NamePosition
Chirayu AminChairman
Rati DesaiNon Executive Independent Director
View More

Alembic FAQs

The Buying Price of Alembic share is 89.95 For live prices and instant trading, you can log in to your Choice trading account or open a Free Demat account with Choice.

To buy Alembic stocks, log in to your Choice trading account. If you don’t have one, open a Choice Demat account. Then, add funds, search for Alembic, choose your preferred order type, and place the trade.

The Price-to-earnings (P/E) ratio of Alembic shares is 7.24. You can compare it with the sector average for relative valuation.

The Price to Book (P/B) ratio Alembic shares is 0.9. Useful to assess the stock's value relative to its book value.

To assess Alembic’s valuation compare Sector P/E, P/B which are 62.93 & -16.12 with sector averages, along with growth rates and financial metrics.

The Market Cap of Alembic is 2309.75 CR. It indicates the company's size category and trading liquidity.

The 52 week high and low prices of Alembic share price is 92.10 & 0.00. They indicate price extremes, trading ranges, volatility measures, potential support/resistance, and price momentum.

Alembic belongs to the Real Estate sector.

Invest with Zero-Cost Demat Account

Zero AMC for First Year
Free Research Calls
₹ 0 Trade & Call Fee
Zero-Cost